• What Can Be Inferred from the Summary Judgement Ruling [EXPANDED], and Recent Developments

Summary:

Update on section 1.6 from our greater report, entitled "AMRN: Market Headwinds and Inherent Weakness of the Vascepa IP," including expanded analysis of the Summary Judgement ruling pertaining to "Other Health Benefit" claims, i.e., no increase in LDL-C and decrease in apoB, as well as inclusion and analysis of recent motions in limine and exhibit alleging Amarin may be guilty of inequitable conduct.


TOTAL LENGTH: 39 PAGES; 13,622 WORDS; 46 CITATIONS


What Can Be Inferred from the Summary Judgement Ruling [EXPANDED], and Recent Developments

  • Product Code: Section 1.6 AMRN Report UPDATE
  • Availability: In Stock
  • $0.00


Tags: AMRN, Amarin, AMRN report, Amarin Corp